FULC - Fulcrum Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.36
-0.13 (-1.13%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close11.49
Open11.21
Bid0.00 x 800
Ask0.00 x 800
Day's Range10.72 - 11.56
52 Week Range8.19 - 15.94
Volume84,452
Avg. Volume127,212
Market Cap321.456M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-7.21
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Company News For Aug 20, 2019
    Zacks

    Company News For Aug 20, 2019

    Companies in the news are: EL, PANW, WB and FULC

  • GlobeNewswire

    Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD

    CAMBRIDGE, Mass., Aug. 19, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it has initiated ReDUX4, a Phase 2b clinical trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD). “We are excited to evaluate losmapimod’s efficacy and safety in FSHD, a disease for which there are currently no approved treatments,” said Robert J. Gould, Ph.D., Fulcrum’s president and chief executive officer.

  • GlobeNewswire

    Fulcrum Therapeutics to Present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference

    CAMBRIDGE, Mass., Aug. 01, 2019 -- Fulcrum Therapeutics, Inc. (Nasdaq:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with.

  • GlobeNewswire

    Fulcrum Therapeutics Announces Pricing of Initial Public Offering

    CAMBRIDGE, Mass., July 17, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (the “Company”) (Nasdaq:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases, today announced the pricing of its initial public offering of 4,500,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $72.0 million, before underwriting discounts and commissions and offering expenses payable by the Company. In addition, the Company has granted the underwriters a 30-day option to purchase up to 675,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.

  • Benzinga

    IPO Outlook For The Week: Biotechs, Financial Advisers, Medical Services And The Twitch Of China

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Douyu International Holdings Ltd (DOYU) will issue nearly 67.4 million ...

  • Benzinga

    Fulcrum Therapeutics IPO: What You Need To Know

    Cambridge, Massachusetts-based Fulcrum Therapeutics, Inc. is planning a 4.5-million-share IPO at an estimated price range of $16-$18, according to the S-1/A filed with the SEC July 8. The company uses its product engine to identify targets that can be drugged by small molecules, regardless of the particular underlying mechanism of gene misexpression. The company said it is planning to initiate a Phase 2b clinical trial of losmapimod, its product candidate for facioscapulohumeral muscular dystrophy, in mid-2019.